Lexeo Therapeutics (LXEO) Free Cash Flow (2022 - 2026)

Lexeo Therapeutics has disclosed Free Cash Flow across 5 years of filings, most recently posting -$21.2 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$21.2 million, up 2.47% year-over-year; the trailing twelve-month figure through Mar 2026 was -$98.3 million (down 11.34% YoY), and the FY2025 annual result was -$99.0 million, down 21.22% from the prior year.
• Free Cash Flow came in at -$21.2 million for Q1 2026 at Lexeo Therapeutics, down from -$20.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$13.2 million in Q2 2023 to a low of -$29.8 million in Q3 2025.
• The 5-year median for Free Cash Flow is -$19.2 million (2023), against an average of -$19.9 million.
• Across the five-year window, Free Cash Flow sank 104.88% in 2024 and jumped 30.27% in 2025, its largest moves.
• Lexeo Therapeutics' Free Cash Flow stood at -$16.8 million in 2022, then advanced by 16.59% to -$14.1 million in 2023, then tumbled by 104.88% to -$28.8 million in 2024, then jumped by 30.27% to -$20.1 million in 2025, then retreated by 5.48% to -$21.2 million in 2026.
• The last three Free Cash Flow figures came in at -$21.2 million (Q1 2026), -$20.1 million (Q4 2025), and -$29.8 million (Q3 2025), per Business Quant data.